Laboratory set up in Berlin and strategic collaboration with leading German and Danish cancer coorporative groups entered to develop precision medicine for women’s cancers

Press release

Hoersholm, Denmark and Cambridge, MA, US, March 29, 2019 – Oncology Venture A/S (“OV” or “the Company”), today announces a new important strategic collaboration to develop precision medicine for women’s cancers with a huge medical need. The collaboration will enhance the speed of patient inclusion in clinical trials. Two leading cancer coorporative groups – German NOGGO and Danish DBCG – will provide patients with opportunities for individualized investigational treatments based on Oncology Venture’s DRP® prediction technology and its pipeline of precision drug candidates. Oncology Venture has established a fully operational laboratory at the Charité University hospital in Berlin. 

The aim of the collaboration is to further accelerate inclusion of patients into ongoing and future clinical trials of Oncology Venture’s six precision medicine projects. Patients will be selected for the most appropriate treatment based on DRP® prediction analyses, which will also serve to avoid the use of ineffective drugs and consequentially minimize the risk of unnecessary side effects.

Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO) assembles more than 700 health professionals engaged in improving women’s health in Germany. The Danish Breast Cancer Corporative Group (DBCG) organizes all Danish hospitals that are treating breast cancer patients.

The collaboration with NOGGO includes activation of four major cancer clinical sites in Germany for inclusion of patients to Oncology Venture’s umbrella trials of 2X-121 (PARPi) and Irofulven for ovarian cancer, and LiPlaCis®, 2X-121 (PARPi) and 2X-111 (liposomal anthracycline) for breast cancer. The collaboration includes establishment of a DRP® laboratory at Charité University Hospital in Berlin which is now fully operational and shared data bases that ensures efficient and high quality of data. Furthermore, mutual scientific work is being established to develop Oncology Venture’s PRP® technology platform.

 “I’m very proud of the interest from highly recognized international breast and ovarian cancer expert groups. The hospitals they represent will use Oncology Venture’s response prediction technology to track, match and treat patients with our drug candidates. The aim is to tailor a beneficial treatment to each individual cancer patient. By this collaboration we will gain further speed in our efforts to bring new and better cancer treatments forward,” said Peter Buhl Jensen, CEO, Oncology Venture.

The strategic collaboration announced today between Oncology Venture and DBCG is built on top of ongoing and mutual clinical trials and is expected to improve the access of Danish breast cancer patients to prediction analysis and Oncology Venture’s anticancer drugs”, said Prof. PhD Bent Ejlertsen Chairman of the DBCG Scientific Committee for Medical Therapy.

“I look forward to working with this cross disciplinary technology to provide our physicians with access to data on whether their individual patient will benefit from a specific cancer treatment. We have now established a laboratory that can handle tumor tissue, which will ease the procedures and turnaround time of drug response analyses,” said Dr. med. Elena Ioana Breicu Professor, for translational medicine research in gynecological oncology, Coordinator of the TOC Network, Charité Comprehensive Cancer Center (CCCC), Charité University hospital in Berlin.

“NOGGO is dedicated to find better treatments for our patients. We are diligently working with science that gives the highest hope of a positive outcome, building on the scientific break-throughs we have achieved. I believe that through the collaboration with Oncology Venture we can offer cancer patients a hope for better and more individualized treatment,” said Dr. med. Professor Jalid Sehouli medical director Department of Gynecology, European Competence Center for Ovarian Cancer, Charité University hospital in Berlin.

For further information, please contact:
For investor inquiries
Ulla Hald Buhl
IR & Communications
E-mail: uhb@oncologyventure.com
Telephone +45 21 70 10 49

For media inquiries
Thomas Pedersen
Carrotize PR & Communications
E-mail: tsp@carrotize.com
Telephone +45 60 62 93 90

About Oncology Venture A/S
Oncology Venture A/S is engaged in the research and development of anti-cancer drugs via its wholly-owned subsidiary, Oncology Venture Product Development ApS. Oncology Venture uses Drug Response Prediction – DRP® –to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined and is currently demonstrating promising results in an ongoing phase 2 study prospectively using LiPlaCis and its DRP® to track, match and treat patients with metastatic breast cancer. The DRP® alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are first screened, and only the patients most likely to respond to the treatment will be treated. Via a more well-defined patient group, risks and costs are reduced while the development process becomes more efficient.

The current OV product portfolio includes: LiPlaCis®, a liposomal formulation of cisplatin in an ongoing Phase 2 trial for breast and prostate cancer; 2X-121 a PARP inhibitor in an ongoing Phase 2 for breast cancer; dovitinib, which will enter Phase 2 trials for indications dependent on further Dovitinib-DRP retrospective/prospective analysis of studies completed by Novartis. 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; irofulven, a Phase 2 is ongoing for prostate cancer; and APO010, an immuno-oncology product in Phase 1/2 for multiple myeloma. 

Oncology Venture has spun out two companies as Special Purpose Vehicles: Oncology Venture U.S. Inc. (previously 2X Oncology Inc.), a US-based precision medicine company focusing on developing 2X-121 and 2X-111, and OV-SPV 2, a Danish company that will test and develop dovitinib. Oncology Venture A/S has an ownership of 92% in Oncology Venture US and 55% of dovitinib with an opportunity to acquire further 30%. 

Learn more at oncologyventure.com

Follow us on social media:

Facebook: https://www.facebook.com/oncologyventure/
LinkedIn: https://www.linkedin.com/company/oncology-venture/
Twitter: https://twitter.com/OncologyVenture

Forward-looking statements 
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Certified Adviser: Sedermera Fondkommission. Epost: ca@sedermera.se, telefon 040-615 14 10

This information is information that Oncology Venture A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on March 29, 2019.

Attachment